icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

Arrowhead & Sarepta Soar: Unveiling the $11.38B Deal

Wesley ParkTuesday, Nov 26, 2024 12:59 pm ET
4min read
Arrowhead Pharmaceuticals and Sarepta Therapeutics have made headlines after announcing a whopping $11.38 billion licensing and collaboration agreement. This strategic partnership has sent both companies' stocks soaring, with investors eager to understand the potential behind this massive deal.

The agreement, inked on November 26, 2024, grants Sarepta exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare genetic diseases. This includes access to Arrowhead's leading Targeted RNAi Molecule (TRiM) platform, capable of deep and durable target-gene knockdown.

In return, Arrowhead receives a transformational amount of capital immediately, with an upfront payment of $825 million, including a $325 million equity investment at a 35% premium. Additionally, Arrowhead will receive $250 million paid over five years, with the potential for $300 million in near-term milestone payments. Furthermore, Arrowhead is eligible for future potential milestone payments up to $10 billion and royalties on sales.

This partnership significantly bolsters both companies' pipelines and business models. For Arrowhead, it provides a strong financial foundation to fund operations and pipeline development. For Sarepta, it expands its portfolio into adjacent therapeutic areas like rare pulmonary disorders and offers the potential for multiple blockbuster opportunities.

The appointment of Doug Ingram, CEO of Sarepta, to Arrowhead's board of directors further strengthens the collaboration. Ingram's experience in drug development, regulatory processes, and commercialization will be invaluable in guiding Arrowhead's transition to a more focused commercial stage.

The deal represents a strategic deployment of capital by Sarepta, affording multiple potential blockbuster opportunities and diversifying its business model across one-time therapies and chronic treatments. With this partnership, both companies are poised for long-term growth and success in the rare disease and genetic medicine space.


BBAI, SMR, APLD, SUM, CAN...Market Cap, Turnover Rate...


In conclusion, the $11.38 billion deal between Arrowhead and Sarepta is a game-changer for both companies. This strategic partnership aligns with the core investment values of stability, predictability, and consistent growth. As a balanced portfolio approach, this deal offers growth and value stock opportunities while extending both companies' cash runways and potential for multiple new drug launches.
Comments

Add a public comment...
Post
User avatar and name identifying the post author
QuantumQuicksilver
11/26
$SRPT News: Sarepta Therapeutics has recently entered into a Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for multiple siRNA Programs at the clinical and preclinical stages. Read more here: https://marketwirenews.com/news-releases/sarepta-therapeutics-announces-global-licensing-and--8868047854709870.html $SRPT
0
Reply
User avatar and name identifying the post author
Searchingstan
11/26
TRiM platform is a game-changer, no cap
0
Reply
User avatar and name identifying the post author
LividAd4250
11/26
Doubling down on $ARWR and $SRPT for long gains
0
Reply
User avatar and name identifying the post author
thelastsubject123
11/26
Big win for $ARWR, just hit the jackpot
0
Reply
User avatar and name identifying the post author
Stevitop
11/26
This deal flips the script on rare diseases 💸
0
Reply
User avatar and name identifying the post author
portrayaloflife
11/26
Sarepta's move is pure genomics genius, y'all
0
Reply
User avatar and name identifying the post author
THenrich
11/26
$11.38B for a deal? Crazy, but Sarepta's move seems smart. They're not just resting on EXONDYS 51, adding more fire to their pipeline.
0
Reply
User avatar and name identifying the post author
Longjumping_Rip_1475
11/26
This deal is 🔥 for $ARWR and $SRPT. Anyone else thinking this could be the next big play in gene therapy?
0
Reply
User avatar and name identifying the post author
maximalsimplicity
11/26
Arrowhead and Sarepta dropping big 💰. $11.38 billion deal makes them a solid play. Those RNAi molecules are like a cheat code for gene therapy. Might have to reconsider my small cap portfolio balance. 🤔
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App